Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi Delivery Technologies. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a wide variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of this platform delivery technology, as well as advancement of its own therapeutic programs for the treatment of Leukemia and Glioblastoma.